Cytomegalovirus-associated Portal Vein Thrombosis in an Immunocompetent Patient

被引:0
作者
Atarieh, Menas [1 ,2 ]
Raz-Pasteur, Ayelet [1 ,2 ]
机构
[1] Rambam Hlth Care Campus, Dept Internal Med, IL-3109601 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
来源
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2025年 / 27卷 / 02期
关键词
anti-phospholipid syndrome (APLA); cytomegalovirus (CMV); hypercoagulability; portal vein thrombosis; RISK-FACTORS; INFECTION; ANTIBODIES; PEPTIDE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 38-year-old immunocompetent male with a history of Hodgkin's lymphoma in remission presented to the emergency department at Rambam Hospital with infectious mononucleosis due to an acute cytomegalovirus (CMV) infection. He was also diagnosed with portal vein thrombosis (PVT). After a thorough laboratory and radiological investigation, these two diagnoses were found to be related. No other explanation was identified except for transiently detected antiphospholipid antibodies, which were assumed to be provoked by the CMV infection. In this review, we investigated the relationship between CMV infection and a hypercoagulable state. We searched the PubMed database for case reports, clinical reviews, and meta-analyses that reviewed the relationship between CMV infection and deep vein thrombosis. The incidence of thromboembolism in patients with acute CMV infection was reported to be as high as 6.4%. In addition, anti-cardiolipin antibodies were more commonly present at the time of PVT diagnosis among CMV-positive patients compared to CMV-negative patients, although these antibodies disappeared in most cases. To the best of our knowledge, there is no evidence of added benefit from antiviral therapy in patients with CMV-associated thrombosis. CMV infection may serve as a trigger for a transient hypercoagulable state.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 28 条
[1]   How I treat splanchnic vein thrombosis [J].
Ageno, Walter ;
Dentali, Francesco ;
Squizzato, Alessandro .
BLOOD, 2014, 124 (25) :3685-3691
[2]   Incidence of Cytomegalovirus-associated thrombosis and its risk factors: A case-control study [J].
Atzmony, Lihi ;
Halutz, Ora ;
Avidor, Boaz ;
Finn, Talya ;
Zimmerman, Ofer ;
Steinvil, Arie ;
Zeltser, David ;
Giladi, Michael ;
Justo, Dan .
THROMBOSIS RESEARCH, 2010, 126 (06) :E439-E443
[3]   Cytomegalovirus-associated splanchnic vein thrombosis in immunocompetent patients: A systematic review [J].
Bertoni, Michele ;
Squizzato, Alessandro ;
Foretic, Marina ;
Zanieri, Samanta ;
Di Natale, Massimo Edoardo .
THROMBOSIS RESEARCH, 2018, 168 :104-113
[4]   CYTOMEGALOVIRUS-INFECTION WITH PERFUSION DEFECTS ON THE LUNG-SCAN [J].
BOERS, M ;
HAAK, A .
INFECTION, 1984, 12 (04) :265-267
[5]   Cytomegalovirus (CMV)-associated portal vein thrombosis in a healthy, immunocompetent man [J].
Burkey, Caroline ;
Teng, Catherine ;
Hussein, Khalil Ian ;
Sabetta, James .
BMJ CASE REPORTS, 2020, 13 (12)
[6]   Risk factors of venous thrombo-embolism during cytomegalovirus infection in immunocompetent individuals. A systematic review [J].
Ceccarelli, Manuela ;
Rullo, Emmanuele Venanzi ;
Nunnari, Giuseppe .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (03) :381-390
[7]   Molecular therapeutics - Methotrexate and its mechanism of action [J].
Cronstein, BN .
ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :1951-1960
[8]  
De Broucker C, J Hepato12022, V76, P115
[9]   The significance of autoantibodies against β2-glycoprotein I [J].
de Groot, Philip G. ;
Urbanus, Rolf T. .
BLOOD, 2012, 120 (02) :266-274
[10]   Antiviral therapy of primary cytomegalovirus infection with vascular thrombosis in immunocompetent adults [J].
Deconinck, L. ;
Flateau, C. ;
Pichenot, M. ;
Morell-Dubois, S. ;
Maillard, H. ;
Hatron, P. -Y. ;
Guery, B. ;
Faure, K. .
MEDECINE ET MALADIES INFECTIEUSES, 2016, 46 (02) :87-92